Fibrosis Detection in Heart and Lung Conditions Using 18F-FAPI-74 PET/CT
This study is looking for people aged 18 and older with heart or lung conditions that can cause scarring (fibrosis). Researchers want to see if a new imaging tracer, called 18F-FAPI-74, can find this scarring earlier than current imaging methods. You would have a special scan called an 18F-FAPI-74 PET/CT, along with standard scans like a chest CT. The goal is to compare how well 18F-FAPI-74 PET/CT detects fibrosis compared to these standard scans. You would have an initial scan and then another 8 to 12 months later. The study aims to enroll 210 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention (the 18F-FAPI-74 PET/CT scan). It plans to enroll 210 participants.
- What's involved
- You would have 6 clinic visits over 2 years, including an initial 18F-FAPI-74 PET/CT scan and a follow-up scan 8 to 12 months later.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will have a follow-up scan 8 to 12 months after your initial scan to assess changes.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anthony F Suffredini, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To compare 18F-FAPI-74 PET/CT to standard of care imaging (non-contrast chest CT and 18F-FDG-PET/CT, cardiac MRI for heart cohort) to detect fibrosis.Initial scan, Baseline, 8-12 months
Compare 18F-FAPI-74 PET/CT to standard of care (SOC) imaging with 18F-FDG-PET/CT with the rate of concordance defined as a quantitative measure of the abnormal lung parenchyma detected in both the FAPI and FDG PET scans ranging from 0 to 100% and cardiac MRI for heart cohort for the development of pulmonary or cardiovascular fibrosis at baseline.